TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.

Charlotte I Stroes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.